Literature DB >> 12715130

[Guidelines for German urologists on diagnosis of benign prostate syndrome].

R Berges, K Dreikorn, K Höfner, U Jonas, K U Laval, S Madersbacher, M C Michel, R Muschter, M Oelke, L Pientka, C Tschuschke, U Tunn, K Schalkhäuser, B Göckel-Beining, A Heidenreich, H Rübben, K Schalkhäuser, W Thon, J Thüroff, W Weidner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12715130     DOI： 10.1007/s00120-003-0319-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  68 in total

1.  Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia.

Authors:  M R Feneley; W D Dunsmuir; J Pearce; R S Kirby
Journal:  Urology       Date:  1996-05       Impact factor: 2.649

2.  The principles and clinical application of advanced urodynamic analysis for BPH.

Authors:  U Jonas; G Kramer; K Höfner
Journal:  Prog Clin Biol Res       Date:  1994

Review 3.  Objective evaluation of bladder outlet obstruction.

Authors:  P Abrams
Journal:  Br J Urol       Date:  1995-07

4.  Formula-derived prostate volume determination.

Authors:  R G Aarnink; J J de la Rosette; F M Debruyne; H Wijkstra
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

5.  Rating the quality of evidence for clinical practice guidelines.

Authors:  D C Hadorn; D Baker; J S Hodges; N Hicks
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

Review 6.  The role of urodynamic study in the evaluation and management of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  G S Gerber
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

7.  The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness.

Authors:  C Manieri; S S Carter; G Romano; A Trucchi; M Valenti; A Tubaro
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

Review 8.  Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?

Authors:  M C Hall; C G Roehrborn; J D McConnell
Journal:  Semin Urol Oncol       Date:  1996-08

9.  Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.

Authors:  W P Witjes; M J de Wildt; P F Rosier; C T Caris; F M Debruyne; J J de la Rosette
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

10.  Correlation between micturitional urethral pressure profile and pressure-flow criteria in bladder outlet obstruction.

Authors:  C E DuBeau; M P Sullivan; E Cravalho; N M Resnick; S V Yalla
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450
View more
  11 in total

1.  [Benign prostate hyperplasia].

Authors:  U Jonas; A I Gabouev; T R W Herrmann; K Höfner; M C Michel; M Alschibaja; R Hartung
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  [New developments for benign prostate syndrome].

Authors:  K Höfner
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

Review 3.  [Surgical and instrumental management of benign prostatic hyperplasia].

Authors:  R Muschter; O Reich
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

4.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

5.  [Urology update seminar UroUpdate. Düsseldorf 27th-28th February 2009].

Authors:  U Ayazpoor
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

Review 6.  [Diagnostics of benign prostate syndrome].

Authors:  M Seitz; A Herlemann; G Magistro; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

7.  Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.

Authors:  K Höfner; M Burkart; G Jacob; U Jonas
Journal:  World J Urol       Date:  2009-12-10       Impact factor: 4.226

Review 8.  [Treatment of LUTS in BPS. When and when not to administer pills?].

Authors:  R Berges
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

9.  [German guidelines for the assessment of BPH. What's new in 2007?].

Authors:  M Oelke; M C Michel; K Höfner
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

10.  Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.

Authors:  Jae-Seung Paick; Soo Woong Kim; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.